OnCo

Trastuzumab deruxtecan 5.4 mg/kg

Checked 2026-09-09

HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC

One cycle

every 21 days
178141521Trastuzumab deruxtecan: 5.4 mg/kg (6.4 mg/kg in gastric cancer), IntravenousTrastuzumab deruxtecan
21-day cycle, until progressionIntravenous

Components

DrugDoseRouteDays
5.4 mg/kg (6.4 mg/kg in gastric cancer)IVD1
Cycles
until progression
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine

Notes

  • Interstitial lung disease in about 10-15%: hold for any grade, permanently discontinue for grade 2 or above.
  • Moderately emetogenic: three-drug antiemetic prophylaxis is recommended.

Used in

Source

DESTINY-Breast04, NEJM 2022

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers